

Who We Are

Precision Epigenomics is here to support your health with advanced technology designed to detect even the most serious cancers at their earliest stages, all through a simple blood draw. Our **EPISEEK** cancer screening is quick, accurate, and affordable, providing you with answers about your health and peace of mind for the future. At Precision Epigenomics, you're more than a patient—you're at the heart of everything we do, and we're dedicated to helping you live well.




Precision Epigenomics' liquid biopsy test, **EPISEEK**™, is a blood-based screening tool
designed to detect circulating tumor DNA
(ctDNA)—DNA shed by tumors. EPISEEK™
focuses on cancer-specific, abnormally
methylated cell-free DNA, using a proprietary set
of biomarkers unique to cancer cells and absent
in normal cells.

With advanced software for analyzing epigenomic modifications, **EPISEEK**™ offers a cost-effective, precise, and minimally invasive approach that may detect cancer earlier and is more accessible than traditional tissue biopsies.

EPISEEK[™] screens for all major cancer types, including those without existing early detection or screening methods. By examining tumor-specific DNA methylation patterns, this liquid biopsy provides reliable cancer screening.*

***EPISEEK**™ is faster, is less expensive, and detects brain cancer unlike other tests on the market.

*The EPISEEK™ blood test is based on peer-reviewed scientific publications and presentations.+



*The EPISEEKTM test may not identify signals for every type of cancer at every stage. There is a possibility of false positive or false negative results.



Who Is EPISEEK[™] For?

The **EPISEEK**™ test is recommended for . . .

- Those with an elevated risk of cancer
- Individuals aged 45 or older

The test is not recommended for . . .

- · Individuals who are pregnant
- Individuals aged 21 years or younger
- Individuals undergoing active cancer treatment or those with an active known malignancy

We encourage providers to consider adding EPISEEK[™] cancer screening to their patients' annual checkups!

How It Works

More than just an early cancer detection test—it's peace of mind!



+ Literature Supporting EPISEEK

Vrba L., Futscher BW. "A suite of DNA methylation markers that can detect most common human cancers." *Epigenetics* 2018;13(1):61-72. doi:10.1080/15592294.2017.1412907

Vrba L., Oshiro MM, Kim SS, et al. "DNA methylation biomarkers discovered in silico detect cancer in liquid biopsies from non-small cell lung cancer patients." *Epigenetics*. 2020:15/4):419-430. doi:10.1080/15592294.2019.1695333

Vrba L., Futscher BW, Oshiro M., et al. "Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease." Clin *Epigenetics*. 2022;14(1):28. Published 2022 Feb 22. doi:10.1186/s13148-022-01246-2

Vrba L., Futscher BW, Bernert R., et al. "Sentinel-10 – a new multi-cancer early detection test." *The Journal of Molecular Diagnostics* 2022 Nov;22(10):S155-173 doi: 10.1016/S1525-1578/22(10):S155-173 doi: 10.1016/S1525-1578/22(10):S155-1578/22(10):

Routh J., Bernert R., Fortin Ensign S. "Evaluation of a multicancer early detection test for identifying circulating tumor DNA in plasma of glioblastoma patients using bisulfite conversion and methylation-specific PCR." *The Journal of Molecular Diagnostics* 2024 Nov;26(11):S1525-1578 doi: 10.1016/S1525-1578(24)00230-7

Ask about a Multi-Cancer Detection Test

At Precision Epigenomics, we're dedicated to bringing you the latest in healthcare technology to help detect even the most serious cancers at their earliest stages so you can focus on what matters most.

Speak to your provider about ordering the **EPISEEK**™ early cancer screening test today!



Visit us at **precision-epigenomics.com**. Have questions? Let's talk.



support@precision-epigenomics.com 520.372.7522